Yutaka Kawaguchi

ORCID: 0009-0001-6543-9685
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Silkworms and Sericulture Research
  • Silk-based biomaterials and applications
  • Neurobiology and Insect Physiology Research
  • Insect Utilization and Effects
  • Viral Infectious Diseases and Gene Expression in Insects
  • Insect Resistance and Genetics
  • Insect and Arachnid Ecology and Behavior
  • CRISPR and Genetic Engineering
  • Invertebrate Immune Response Mechanisms
  • Animal Genetics and Reproduction
  • Chromosomal and Genetic Variations
  • Gout, Hyperuricemia, Uric Acid
  • Aldose Reductase and Taurine
  • Metabolism and Genetic Disorders
  • Erythropoietin and Anemia Treatment
  • Protein Hydrolysis and Bioactive Peptides
  • Hemiptera Insect Studies
  • Identification and Quantification in Food
  • Diabetes Treatment and Management
  • RNA Research and Splicing
  • Dialysis and Renal Disease Management
  • Plant Virus Research Studies
  • Heat shock proteins research
  • Pancreatic function and diabetes
  • Blood transfusion and management

Kobe University
2024

Mitsubishi Group (Japan)
2016-2021

Mitsubishi Tanabe Pharma Corporation
2016-2021

Kyushu University
2002-2011

The Dainippon Silk Foundation
2003-2010

Graduate School of Health Care Sciences, Jikei Institute
2010

Kajima Corporation (Japan)
2010

Mitsubishi Heavy Industries (Germany)
2007

Sericultural Research Institute
1996

Kumamoto University
1991-1995

Standard care for treating anemia in patients with CKD includes use of erythropoiesis-stimulating agents, which sometimes involves increased risks cardiovascular morbidity and mortality. Previous studies nondialysis-dependent (NDD-CKD) found significantly elevated hemoglobin levels vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, compared placebo.In this phase 3, open-label, active-controlled noninferiority trial, we randomized 304 Japanese adults NDD-CKD (including...

10.1681/asn.2020091311 article EN Journal of the American Society of Nephrology 2021-04-21

Combination therapy with canagliflozin and insulin was investigated in a prescribed substudy of the Cardiovascular Assessment Study (CANVAS); however, it not evaluated Japanese patients type 2 diabetes mellitus (T2DM). Since usage profile pathologic features differ from those Caucasian patients, we determined clinical benefit such combination patients. Patients who had inadequate glycemic control despite insulin, diet exercise therapies were randomized into placebo (n = 70) 100 mg 76) groups...

10.1186/s12933-016-0407-4 article EN cc-by Cardiovascular Diabetology 2016-06-18

Vadadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor that stimulates erythropoiesis.The efficacy and safety of vadadustat, compared with darbepoetin alfa, was determined in a Phase 3 double-blind study Japanese anemic patients on hemodialysis. Patients receiving erythropoiesis-stimulating agents (ESAs) were randomized switched to either vadadustat or alfa for 52 weeks. Doses adjusted maintain hemoglobin (Hb) level 10.0-12.0 g/dL. The primary endpoint average Hb at...

10.1093/ndt/gfab055 article EN cc-by-nc Nephrology Dialysis Transplantation 2021-02-25

The silk gland of Bombyx mori is an organ specialized for the synthesis and secretion proteins. We report here resolution proteins by 2-DE identification many those This was accomplished dissecting glands into several sections, with each exhibiting more than 400 protein spots 2-DE, which 100 were excised characterized in-gel digestion followed PMF. Ninety-three tentatively identified. These then categorized groups involved in secretion, transport, lipid metabolism, defense, etc. Western...

10.1002/pmic.200500348 article EN PROTEOMICS 2006-03-20

Vadadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor for the treatment of anemia in patients with chronic kidney disease (CKD). This phase 3, open-label, 24-week single-arm study evaluated efficacy and safety vadadustat 42 Japanese CKD undergoing peritoneal dialysis. Patients received 24 weeks, initiated at 300 mg/day doses were adjusted to achieve target hemoglobin (Hb) range 11.0-13.0 g/dL. Least squares mean average Hb weeks 20 was 11.35 g/dL, which within range....

10.1111/1744-9987.13611 article EN Therapeutic Apheresis and Dialysis 2020-12-07

The sodium-glucose cotransporter 2 inhibitor, canagliflozin, reduced kidney failure and cardiovascular events in the Canagliflozin Renal Events Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) trial. We carried out a post-hoc analysis to evaluate efficacy safety of canagliflozin subgroup participants East South-East Asian (EA) countries who are at high risk renal complications.

10.1111/jdi.13624 article EN cc-by-nc Journal of Diabetes Investigation 2021-07-02

The telomere structures in Bombyx mori are thought to be maintained mainly by the transposition of specialized telomeric retroelements SART and TRAS. silkworm genome has TTAGG repeats telomerase, but this telomerase displays little or no activity. Here, we report that transcription SART1 TRAS1 is suppressed Piwi subfamily proteins BmAgo3 Siwi. was found expressed predominantly gonads early embryo, as other model organisms, BmN4 cultured cells, these formed granules were separate from nuage,...

10.2478/s11658-009-0038-9 article EN cc-by-nc-nd Cellular & Molecular Biology Letters 2009-11-27

Sodium‐glucose co‐transporter‐2 (SGLT2) inhibitors and glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) are antihyperglycaemic agents with weight‐lowering effects. The efficacy safety of the SGLT2 inhibitor canagliflozin as add‐on therapy in Japanese patients type 2 diabetes mellitus (T2DM) inadequate glycaemic control a GLP‐1RA (≥12 weeks) were evaluated this phase IV study. Patients received 100 mg once daily for 52 weeks. Efficacy endpoints included change glycated haemoglobin...

10.1111/dom.13267 article EN cc-by-nc Diabetes Obesity and Metabolism 2018-02-23

Cecropins belong to the antibacterial peptides family and are induced after injection of bacteria or their cell-wall components. By silkworm cDNA microarray analysis, a novel type Cecropin gene was identified as up-regulated in early embryo, 1 day oviposition. The isolated 394 bp with 198 ORF translating 65 amino acids, encoding BmCecropin-E (BmCec-E). Using Southern hybridization genome search number BmCec-E estimated be at least two per haploid, which consisted exons, other members. mRNA...

10.1271/bbb.80082 article EN Bioscience Biotechnology and Biochemistry 2008-08-23

The silkworm is a typical holometabolous insect going through drastic morphological changes upon metamorphosis from larvae to pupae. Comprehensive studies focusing on the help elucidate understanding of biogenic mechanism. Here, we report initial profile intersegmental muscle (ISM) proteins during larval-pupal metamorphosis. In total, 258 protein spots were resolved by two-dimensional gel electrophoresis (2-DE). Fifty-seven larval identified, where 3 exclusively detected in samples....

10.1021/pr070071y article EN Journal of Proteome Research 2007-05-12

10.1016/s1096-4959(02)00153-7 article EN Comparative Biochemistry and Physiology Part B Biochemistry and Molecular Biology 2002-11-01

10.1016/j.cbpc.2004.06.013 article EN Comparative Biochemistry and Physiology Part B Biochemistry and Molecular Biology 2004-08-27

Abstract The AHA1 (activator of Hsp90 ATPase) family proteins were exclusively conserved from yeast to humans, but little is known about their tissue distribution or biological function. In this study, a cDNA for Bombyx mori homologue, BmAHA1, was isolated the testes larvae on day 3 fifth instar using an mRNA differential display method. This encodes protein with 341 amino acid residues. Gene expression studies revealed that BmAHA1 occurred prominently in testes. situ hybridization and...

10.1111/j.1365-2583.2005.00553.x article EN Insect Molecular Biology 2005-04-26
Coming Soon ...